Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients

Iftimi, Adina; Rodríguez‐Bernal, Clara L.; Peiró, Salvador; Bonanad, Santiago; Ferrero‐Gregori, Andreu; Hurtado, Isabel; García‐Sempere, Aníbal; Sanfélix‐Gimeno, Gabriel

doi:10.1002/cpt.2362

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10,11] However, observational studies examining whether treatment with antiplatelet or anticoagulant medication reduces risks of cancer have shown conflicting results. [12][13][14] Attempts to elucidate complex causal relationships between VTE and cancer using traditional observational studies are complicated by difficulties in ascertaining direction of causality, in addition to being susceptible to unmeasured and residual confounding from risk factors which are common to both VTE and cancer, including smoking, obesity and co-existing inflammatory conditions. [2] Mendelian randomisation (MR) analysis addresses some of these limitations.…”

Section: Introductionmentioning

confidence: 99%

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomisation analysis

Cornish

Haycock

Brenner

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: People with cancer experience high rates of venous thromboembolism (VTE). Additionally, risk of subsequent cancer is increased in people experiencing their first VTE. The causal mechanisms underlying this association are not completely understood, and it is unknown whether VTE is itself a risk factor for cancer. Methods: We used data from large genome-wide association study meta-analyses to perform bi-directional Mendelian randomisation analyses to estimate causal associations between genetically-proxied lifetime risk of VTE and risk of 18 different cancers. Results: We found no conclusive evidence that genetically-proxied lifetime risk of VTE was causally associated with an increased incidence of cancer, or vice-versa. We observed an association between VTE and pancreatic cancer risk (odds ratio for pancreatic cancer 1.23 (95% confidence interval 1.08 - 1.40) per log-odds increase in risk of VTE, P = 0.002). However, sensitivity analyses revealed this association was predominantly driven by a variant proxying non-O blood group, with inadequate evidence from Mendelian randomisation to suggest a causal relationship. Conclusions: These findings do not support the hypothesis that genetically-proxied lifetime risk of VTE is a cause of cancer. Existing observational epidemiological associations between VTE and cancer are therefore more likely to be driven by pathophysiological changes which occur in the setting of active cancer and anti-cancer treatments. Further work is required to explore and synthesise evidence for these mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomisation analysis

Cornish

Haycock

Brenner

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomization analysis

Cornish,

Haycock,

Brenner

et al. 2023

International Journal of Epidemiology

View full text Add to dashboard Cite

Background People with cancer experience high rates of venous thromboembolism (VTE). Risk of subsequent cancer is also increased in people experiencing their first VTE. The causal mechanisms underlying this association are not completely understood, and it is unknown whether VTE is itself a risk factor for cancer. Methods We used data from large genome-wide association study meta-analyses to perform bidirectional Mendelian randomization analyses to estimate causal associations between genetic liability to VTE and risk of 18 different cancers. Results We found no conclusive evidence that genetic liability to VTE was causally associated with an increased incidence of cancer, or vice versa. We observed an association between liability to VTE and pancreatic cancer risk [odds ratio for pancreatic cancer: 1.23 (95% confidence interval: 1.08–1.40) per log-odds increase in VTE risk, P = 0.002]. However, sensitivity analyses revealed this association was predominantly driven by a variant proxying non-O blood group, with inadequate evidence to suggest a causal relationship. Conclusions These findings do not support the hypothesis that genetic liability to VTE is a cause of cancer. Existing observational epidemiological associations between VTE and cancer are therefore more likely to be driven by pathophysiological changes which occur in the setting of active cancer and anti-cancer treatments. Further work is required to explore and synthesize evidence for these mechanisms.

show abstract

Prevalence, incidence and impact of cancer in atrial fibrillation: a systematic review and meta-analysis of 6,600,000 patients

Mao,

Wang,

Fan

et al. 2024

Preprint

View full text Add to dashboard Cite

Aims Contemporary studies have indicated that atrial fibrillation (AF) is common among cancer patients, and affects the prognosis of cancer patients. The other hand, AF and cancer share the same risk factors, while the prevalence, incidence and impact of cancer in AF patients is unclear. Our aim was to estimate the prevalence and incidence of cancer, and focus on the impact of cancer on clinical outcome. Methods and Results We searched the PubMed, Web of science, Embase and Cochrane Library databases, and conducted according to international guidelines to perform a system review and meta-analysis. All studies reporting the prevalence and incidence of cancer were included. We extracted the data from these studies and used the random effect model to pool the result. The prevalence and incidence of cancer overall were 1153.31 (95%CI: 959.19-1380.72) per 10000 patients, 173.28 (95%CI: 131.89-227.66) per 10000 person-years, respectively. Otherwise, cancer prevalence and incidence had been shown to vary by cancer type, the incidence also varies gender and comorbidities. And cancer is associated with higher risk of all-death (OR: 1.78, 95%CI: 1.51–2.08) and bleeding (OR: 1.44, 95%CI: 1.26–1.65), no significant differences in cardiovascular death and stroke/system embolism. Conclusions Cancer is common in AF patients, affecting 11% of patients. The incidence of cancer cannot be ignored. Cancer is associated with the worse outcome in AF patients, with more than 1.7-flod higher risk of all-death and increased the risk of bleeding.

show abstract

Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients

Cited by 4 publications

References 31 publications

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomisation analysis

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomisation analysis

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomization analysis

Prevalence, incidence and impact of cancer in atrial fibrillation: a systematic review and meta-analysis of 6,600,000 patients

Contact Info

Product

Resources

About